Holen Sie sich die Stockscreener-App
1.66
1.19%
-0.02
Handel nachbörslich:
1.66
Schlusskurs vom Vortag:
$1.68
Offen:
$1.69
24-Stunden-Volumen:
490.58K
Relative Volume:
0.69
Marktkapitalisierung:
$74.91M
Einnahmen:
$1.49M
Nettoeinkommen (Verlust:
$-12.27M
KGV:
-5.006
EPS:
-0.3316
Netto-Cashflow:
$-11.30M
1W Leistung:
-1.78%
1M Leistung:
+16.90%
6M Leistung:
+50.91%
1J Leistung:
+41.88%
1-Tages-Spanne:
$1.6454
$1.725
1-Wochen-Bereich:
$1.53
$1.7999
52-Wochen-Spanne:
$0.7006
$2.59
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.66 | 74.91M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
RNXT Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, Yet Shares SlipEarnings Revision Downgrade - dars.gov.et
CFO of RenovoRx (RNXT) awarded 80,000 RSUs - Stock Titan
RNXT: Strong commercial growth and clinical data position RenovoCath for major oncology market impact - TradingView
RenovoRx Inc. (RNXT) Falls 6.15% to $2.24 as Stock Approaches Key Support LevelCommon Gap - careplusvn.com
$RenovoRx (RNXT.US)$ - Moomoo
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - Investing News Network
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline - Yahoo Finance
Biotech Stocks At 52-Week HighsRNXT +15%, EOLS, CRNX, APGE - RTTNews
RenovoRx publishes pharmacokinetic data from Phase III trial By Investing.com - Investing.com Canada
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - Investing News Network
Transcript : RenovoRx, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
RenovoRx (RNXT) Earnings Update: Reported EPS Tops Expectations at the Close; Post-Report: The Stock Finishes Near Unchanged in the Latest SessionShort-Term Outlook - vinanet.vn
RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update - Kalkine Media
RenovoRx regains Nasdaq minimum bid price compliance - Investing.com
RenovoRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com UK
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo! Finance Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Investing News Network
RenovoRx receives U.S. patent allowance for cancer device - Investing.com
RenovoRx receives U.S. patent allowance for cancer device By Investing.com - Investing.com Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment - marketscreener.com
RenovoRx Advances Targeted Localized Therapy for Advanced Pancreatic Cancer - geneonline.com
HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - sharewise.com
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings: Narrower-than-Expected Loss Drives 11% Share RallyForward Guidance Trends - vinanet.vn
RNXT Q2 2026 Earnings: Narrower Loss Beats Estimate, Shares Jump 11%Share Dilution Risk - vinanet.vn
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - The Manila Times
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-RenovoRx Q2 Net Income USD -2.911 Million - TradingView
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RNXT Q2 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineFiscal Year Earnings - dars.gov.et
RenovoRx completes enrollment in phase III pancreatic cancer trial By Investing.com - Investing.com UK
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):